Entries by Nitin Sharma

VERO Biotech’s GENOSYL® Delivery System recognized as a “Technological Breakthrough” at Premier, Inc.’s Annual Supplier Innovation Celebration

June 15, 2023 in /by

Vero will be honored as an “Innovative Supplier” at Premier’s Annual Breakthroughs Conference and Exhibition (BREAKTHROUGHS 2023) taking place June 20-22 in Nashville, TN ATLANTA, June 14, 2023 /PRNewswire/ — VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced that it will be honored […]

VERO Biotech’s Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite

February 2, 2023 in /by

Second Generation GENOSYL® DS is the first and only Inhaled Nitric Oxide delivery system that is FDA-approved for rebreathing anesthesia, which provides a significant advantage in patient comfort, helping patients retain heat and moisture 1,2,3 ATLANTA, Feb. 2, 2023 /PRNewswire/ — VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital […]

VERO Biotech Raises $30 Million to Accelerate Commercialization of Its Innovative Tankless Inhaled Nitric Oxide Delivery System

January 11, 2023 in /by

Financing led by Petrichor strengthens VERO Biotech’s position as a leader in neonatal intensive care  ATLANTA, Jan. 11, 2023 /PRNewswire/ — VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced the successful close of a $30 million financing with Petrichor, a leading healthcare-dedicated growth capital provider. The proceeds will support […]

VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System

January 9, 2023 in /by

This novel GENOSYL® system represents another breakthrough in innovative technology with dual-cassette design and secondary adaptive sensor technology to further optimize patient care ATLANTA, Jan. 9, 2023 /PRNewswire/ — VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced FDA approval of the newest generation of its […]

Georgia Bio Awards VERO Biotech the 2022 Golden Helix Innovation Award and Deal of the Year Award

April 27, 2022 in /by

Atlanta-based innovative company is recognized for its flagship product, GENOSYL® Delivery System, and Deal of the Year for securing funding of up to $100 million in a financing round led by MVM Partners (MVM) to support the expanded commercialization of the GENOSYL® Delivery System. ATLANTA, April 27, 2022 /PRNewswire/ — VERO Biotech Inc, an Atlanta, Georgia-based company focused on saving lives, alleviating […]

VERO Biotech Secures $50 Million Funding from Runway Growth Capital

January 25, 2021 in /by

A senior secured term loan will support the further development of VERO Biotech’s GENOSYL® Delivery System, a proprietary tankless and portable delivery system for the administration of GENOSYL® (nitric oxide) gas, for inhalation ATLANTA, Jan. 19, 2021 /PRNewswire/ — VERO Biotech LLC, an Atlanta, Georgia-based biotechnology company focused on saving lives, alleviating suffering, and improving […]

FDA Approves Interhospital Patient Transport Use of VERO Biotech’s GENOSYL® Delivery System, Resulting in the Broadest Label in the Inhaled Nitric Oxide Space

December 22, 2020 in /by

The GENOSYL® DS facilitates patient treatment in interhospital and intrahospital transport, and in diverse diagnostic and imaging settings, representing the broadest FDA approved label in the industry allowing use in the Acute-care Setting including MRI, Ground, Fixed Wing and Rotary Transport. ATLANTA, Dec. 15, 2020 /PRNewswire/ — VERO Biotech LLC, an Atlanta, Georgia-based biotechnology company focused on saving lives, […]